CL
CLIFF.US Cordlife Group Limited
- Market cap
- USD 32.9M
- P/E
- -
- P/B
- 0.42x
- ROE
- -5.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CLIFF.US undervalued?
Graham numberThe Graham number of Cordlife Group Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cordlife Group Limited fundamental analysis
No fundamental analysis for Cordlife Group Limited yet.
Cordlife Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cordlife Group Limited
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric visio…
Full company profileCordlife Group Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cordlife Group Limited annual financial statements (SGD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 60.0M | 68.3M | 60.3M | 45.8M | 59.0M | 56.7M | 55.2M | 55.7M | 27.8M | 38.8M | 34.6M |
| Gross Profit | 37.5M | 45.8M | 36.4M | 28.6M | 29.4M | 28.6M | 37.2M | 37.3M | 11.7M | 21.7M | 19.9M |
| Operating Income | -143K | 4.23M | -6.26M | -2.74M | 7.01M | 6.40M | 4.25M | 2.74M | -20.6M | -15.1M | -6.89M |
| EBITDA | 3.21M | 7.38M | -3.27M | 12.7M | 12.0M | 10.8M | 9.34M | 8.56M | -14.4M | -10.7M | -4.29M |
| Net Income | -2.57M | 3.27M | 1.78M | 4.81M | 6.55M | 6.14M | 4.89M | 3.52M | -18.7M | -12.6M | -5.31M |
| EPS | -0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 | -0.07 | -0.05 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 199M | 218M | 213M | 167M | 176M | 173M | 228M | 228M | 217M | 202M | 199M |
| Total Liabilities | 73.4M | 96.7M | 88.9M | 70.6M | 75.7M | 71.9M | 93.7M | 92.8M | 98.5M | 97.2M | 98.6M |
| Shareholders' Equity | 125M | 125M | 124M | 96.0M | 133M | 136M | 134M | 135M | 118M | 104M | 100M |
| Cash & Short-term Investments | 60.8M | 61.1M | 43.3M | 36.1M | 54.4M | 64.6M | 65.2M | 65.0M | 60.6M | 51.7M | 49.4M |
| Total Debt | 8.73M | 5.44M | 4.61M | 6.79M | 7.65M | 2.97M | 4.25B | 3.51M | 2.43M | 2.03M | 4.32M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.97M | 8.97M | 10.2M | 9.84M | 15.9M | 9.50M | 8.00M | 9.80M | -11.3M | 504K | -2.93M |
| Capital Expenditure | 1.67M | 2.23M | 2.80M | 1.53M | 1.04M | 1.16M | 3.22M | 2.83M | 4.31M | 1.23M | 562K |
| Free Cash Flow | 301K | 6.73M | 7.41M | 8.31M | 12.0M | 7.73M | 4.77M | 6.97M | -15.6M | -728K | -3.49M |
| Ratios | |||||||||||
| ROE | -2.1% | 2.6% | 1.4% | 5.0% | 4.9% | 4.5% | 3.6% | 2.6% | -15.8% | -12.1% | -5.3% |
| ROA | -1.3% | 1.5% | 0.8% | 2.9% | 3.7% | 3.5% | 2.1% | 1.5% | -8.6% | -6.3% | -2.7% |
| Net Profit Margin | -4.3% | 4.8% | 2.9% | 10.5% | 11.1% | 10.8% | 8.9% | 6.3% | -67.1% | -32.5% | -15.4% |
| Debt to Equity | 0.07x | 0.04x | 0.04x | 0.07x | 0.06x | 0.02x | 31.64x | 0.03x | 0.02x | 0.02x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cordlife Group Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 6, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | SGD 71.9K | 0.00 | - |
| 2024 | SGD 74.0K | 0.00 | - |
| 2023 | - | - | - |
| 2022 | USD 2.30M | 0.01 | 47.1% |
| 2021 | SGD 2.30M | 0.01 | 37.5% |
| 2020 | SGD 2.54M | 0.01 | 38.8% |
| 2019 | SGD 1.01M | 0.00 | 21.0% |
| 2018 | SGD 3.28M | 0.01 | 184.8% |
| 2017 | SGD 1.26M | 0.00 | 38.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cordlife Group Limited
- Insiders 75.54%
- Institutions 0.00%
- Public & others 24.46%
- Shares outstanding 256M
- Free float 82.9M
Cordlife Group Limited company profile
- Company name
- Cordlife Group Limited
- Ticker
- CLIFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1 Yishun Industrial Street 1, Singapore, Singapore, 768160
- Phone
- 65 6238 0808
- Website
- cordlife.com
About Cordlife Group Limited
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, and lifestyle genetic screening services for adults. In addition, it offers life sprouts, medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.
Cordlife Group Limited management
9- Ms. Xiaoling ChenGroup CEO & Group Executive Director · born 1991
- Ms. Yifei WuGroup Chief Financial Officer · born 1979
- Ms. Hnin Yi Thet A.C.A.Executive Officer · born 1976
- Ms. Lucy LaiCountry Chief Executive Officer of Healthbaby Hong Kong- Cordlife Hong Kong
- Mr. Raymond WongCountry Chief Executive Officer of Stemlife Malaysia
- Mr. Michael ArnonobalCountry Chief Executive Officer of Cordlife Philippines
- Ms. Retno SuprihatinCountry Chief Executive Officer of Cordlife Idonesia
- Ms. Hui Yee CheokJoint Company Secretary
- Ms. Wei Ling HonJoint Company Secretary